Luca Moscetti
Impact in
- Oncology top 2%
- Lung Cancer Research Studies
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Colorectal Cancer Treatments and Studies
-
- Lung Cancer Treatments and Mutations
- Advanced Breast Cancer Therapies
Papers in
- Oncology 71
- Cancer Treatment and Pharmacology 25
- HER2/EGFR in Cancer Research 24
- Lung Cancer Research Studies 12
- Colorectal Cancer Treatments and Studies 10
-
- Advanced Breast Cancer Therapies 30
- Lung Cancer Treatments and Mutations 17
- Co-authors
- Isabella Sperduti (32 shared papers)Claudia Omarini (29 shared papers)Federico Piacentini (30 shared papers)Flavia Longo (7 shared papers)Calogero Lauricella (3 shared papers)Massimo Broggini (3 shared papers)Mirko Marabese (3 shared papers)Marina Chiara Garassino (4 shared papers)
In The Last Decade
Luca Moscetti
90 papers receiving 1.6k citations
Hit Papers
Peers
Comparison fields: 5 of 78
- Oncology 1.1k
- Pulmonary and Respiratory Medicine 873
- Cancer Research 361
- Genetics 95
- Family Practice 19
Countries citing papers authored by Luca Moscetti
This map shows the geographic impact of Luca Moscetti's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Luca Moscetti with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Luca Moscetti more than expected).
Fields of papers citing papers by Luca Moscetti
This network shows the impact of papers produced by Luca Moscetti. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Luca Moscetti. The network helps show where Luca Moscetti may publish in the future.
Co-authors
The 25 scholars most cited alongside Luca Moscetti, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 98 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial Hit paper breakdown → | 2013 | 376 |
| 2 | 2014 | 86 | |
| 3 | 2005 | 78 | |
| 4 | 2011 | 78 | |
| 5 | 2021 | 64 | |
| 6 | 2023 | 58 | |
| 7 | 2018 | 56 | |
| 8 | 2006 | 52 | |
| 9 | 2014 | 43 | |
| 10 | 2015 | 40 | |
| 11 | 2015 | 40 | |
| 12 | 2012 | 36 | |
| 13 | 2013 | 34 | |
| 14 | 2015 | 31 | |
| 15 | 2014 | 27 | |
| 16 | 2014 | 22 | |
| 17 | 2018 | 21 | |
| 18 | 2019 | 20 | |
| 19 | 2017 | 20 | |
| 20 | 2013 | 19 |
About Luca Moscetti
Luca Moscetti is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Molecular Biology and Genetics, having authored 98 papers that have together received 1.6k indexed citations. Recurring topics across this work include Advanced Breast Cancer Therapies (30 papers), Cancer Treatment and Pharmacology (25 papers), HER2/EGFR in Cancer Research (24 papers), Breast Cancer Treatment Studies (22 papers), Lung Cancer Treatments and Mutations (17 papers), Lung Cancer Research Studies (12 papers), Estrogen and related hormone effects (10 papers) and Colorectal Cancer Treatments and Studies (10 papers). The work is most often cited by research in Oncology (1.1k citations), Pulmonary and Respiratory Medicine (873 citations), Cancer Research (361 citations), Genetics (95 citations) and Family Practice (19 citations). Luca Moscetti has collaborated with scholars based in Italy, Malaysia and Spain. Frequent co-authors include Isabella Sperduti, Claudia Omarini, Federico Piacentini, Flavia Longo, Calogero Lauricella, Massimo Broggini, Mirko Marabese, Marina Chiara Garassino, Olga Martelli and Roberto Labianca. Their work appears in journals such as Annals of Oncology, Journal of Clinical Oncology, Clinical Breast Cancer, Journal of Cancer Research and Clinical Oncology and ESMO Open.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.